Ivemend OverviewFosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 and by the European Medicines Agency (EMA) on January 11 of the same year. See also Aprepitant Casopitant L-733,060 Maropitant Vestipitant References ^ "Drugs.com, FDA Approve...
Read more Ivemend Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fosaprepitant
Recent Ivemend Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 125mg, 40mg, 80mg, 80mg + 125mg
- Emulsion: 130mg/18ml (7.2mg/ml)
- For Suspension: 125mg/kit
- Injection: 130mg, 150mg/vial
- Powder: 115mg/vial, 150mg/vial
- Solution: 125mg